Rheumatoid arthritis (RA) is a chronic inflammatory disease leading to joint destruction.
Cytokines play a key role in its pathogenesis. They contribute to the induction and …

Rheumatoid arthritis (RA) is an autoimmune disease with an unclear pathogenic
mechanism. However, it has been proven that the key underlying risk factor is a genetic …

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects~ 1% of the
Caucasian population. Over the last decades, the availability of biological drugs targeting …

Background The effectiveness of biologics for psoriasis shows heterogeneity among
patients. With pharmacogenetic markers, it might be possible to predict treatment response …

Introduction Methotrexate (MTX) is a folate antagonist and a first-line drug for the treatment
of rheumatoid arthritis (RA). However, in up to 30% of cases, MTX monotherapy is …

The aim of this study was to investigate the influence of clinical and genetic factors on
response to tocilizumab (TCZ) response, remission, low disease activity (LDA) and DAS28 …

In the present study, we aimed to investigate the influence of clinical parameters and single-
nucleotide polymorphisms of interleukin-6 receptor (rs12083537, rs2228145, rs4329505 …

Aim: Identifying the predictors of responsiveness and adverse events in methotrexate (MTX)
treated patients with rheumatoid arthritis (RA) has been the focus of most concern, but still …

Biological disease-modifying anti-rheumatic drugs (bDMARDs) have changed care of
patients with rheumatoid arthritis (RA). However, bDMARDs are costly, can lead to serious …

About 70 genetic studies have already addressed the need of biomarkers to predict the
response of patients with rheumatoid arthritis (RA) to methotrexate (MTX) treatment …